Γρήγορη απάντηση
Oxitan Injection — Oxaliplatin (Celon Laboratories). Platinum-based DNA cross-linking chemotherapy. Third-generation platinum for colorectal cancer (FOLFOX, CAPEOX). Less nephrotoxic than cisplatin; cumulative peripheral neuropathy is dose-limiting. Hospital-administered IV. Strict pre-medication, hydration, and antiemetic protocols.
Αυτό που λαμβάνετε με την MedsBase:
- πιστοποιημένο από τη WHO-GMP κατασκευαστή
- Συσκευασία σε απλό φάκελο χωρίς ενδείξεις
- Παγκόσμια αποστολή
- Αξιολογήθηκε από 1,400+ πελάτες (διαβάστε κριτικές)
📦 Εγγύηση Επαναποστολής: αν η παραγγελία σας δεν έχει φτάσει μέσα σε 20 εργάσιμες ημέρες από την αποστολή, την επαναποστέλλουμε χωρίς πρόσθετο κόστος. Διαβάστε την πολιτική.
Γιατί να παραγγείλετε από τη MedsBase
Oxitan Injection ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.
⚠️ Specialist-supervised cancer therapy — this medication is started, monitored, and stopped by an oncologist or haematologist. Dosing depends on tumour type, stage, body surface area, organ function, and concomitant therapy. Self-treatment is not appropriate; the information below is educational and supports informed conversations with your specialist.
All platinum agents are hospital-administered intravenous chemotherapy under specialist supervision. Self-administration is not appropriate. Pre-medication, hydration, antiemetic regimens, and monitoring are part of the protocol.
Cisplatin: nephrotoxicity (mandatory hyperhydration), severe nausea/vomiting, ototoxicity (especially in children — pre/post audiometry), peripheral neuropathy, electrolyte wasting (Mg, K). Oxaliplatin: cumulative peripheral neuropathy (cold-triggered acute neuropathy is distinctive), less nephrotoxic, less emetogenic. Carboplatin: dose-limiting myelosuppression, AUC-based dosing (Calvert formula).
Συχνές Ερωτήσεις
When is platinum chemotherapy used?
Cisplatin: testicular, ovarian, lung, bladder, head and neck, cervical cancers. Oxaliplatin: colorectal cancer (FOLFOX, CAPEOX). Carboplatin: ovarian, lung, breast, head and neck — typically when cisplatin toxicity profile is unacceptable.
How is it given?
IV infusion in a chemotherapy day-unit. Pre-medication includes antiemetics (5-HT3 antagonist + dexamethasone + NK1 antagonist), IV fluids (cisplatin requires aggressive hydration). Each cycle is 2-4 weeks depending on regimen.
Side effects to expect?
Nausea/vomiting (managed with antiemetics), fatigue, neutropenia, thrombocytopenia, neuropathy (oxaliplatin especially), tinnitus/hearing loss (cisplatin), renal dysfunction (cisplatin).
Pre-medication?
Antiemetics: ondansetron + dexamethasone + (for highly emetogenic regimens) aprepitant. Hydration: 1-3 L of saline before/after cisplatin.
Renal monitoring?
Cisplatin: baseline + before each cycle + weekly during therapy. Stop or switch if creatinine rises >25% from baseline. Magnesium and potassium replacement common.
Hearing test?
Audiometry baseline and as clinically indicated for cisplatin (especially in paediatric, repeated cycles, or pre-existing hearing loss).
Εγκυμοσύνη;
Strongly contraindicated — teratogenic and abortifacient. Effective contraception during and for ≥6 months after for both partners.
Αλληλεπιδράσεις φαρμάκων;
Aminoglycosides + cisplatin: massive nephrotoxicity. NSAIDs + cisplatin: nephrotoxicity. Phenytoin levels may drop with platinum chemo. Always disclose all medications.
Cumulative dose limits?
Cisplatin: stop or switch at cumulative neurotoxicity, ototoxicity, or persistent renal impairment. Oxaliplatin: total dose 850 mg/m² is associated with cumulative neuropathy — protocols typically include planned breaks (FOLFOX 4-6, then re-introduction).
When is treatment stopped?
Tumour response/disease progression dictates duration. Specialist decision based on response evaluation criteria (RECIST), toxicity, and patient goals.
Other Cancer Medications
- Xeloda — capecitabine 500 mg — oral 5-FU prodrug for breast/colorectal/gastric cancers
- Altraz — anastrozole 1 mg — aromatase inhibitor for post-menopausal breast cancer
- Xbira — abiraterone 250 mg — CYP17 inhibitor for metastatic prostate cancer
- Zoldria — zoledronic acid IV — for bone metastases and hypercalcaemia
- Actorise — darbepoetin alfa — for chemotherapy-induced anaemia




























Κριτικές
Δεν υπάρχουν ακόμη κριτικές